BR0214301A - Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos para tratar doenças ou condições, para potencializar um efeito terapêutico de um agente do snc, para melhorar a memória recente de um paciente, para determinar a presença ou ausência de um receptor de gabaa em uma amostra, e para alterar a atividade de transdução de sinal de receptor de gabaa, preparação farmacêutica acondicionada, e, uso de um composto ou sal - Google Patents
Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos para tratar doenças ou condições, para potencializar um efeito terapêutico de um agente do snc, para melhorar a memória recente de um paciente, para determinar a presença ou ausência de um receptor de gabaa em uma amostra, e para alterar a atividade de transdução de sinal de receptor de gabaa, preparação farmacêutica acondicionada, e, uso de um composto ou salInfo
- Publication number
- BR0214301A BR0214301A BR0214301-1A BR0214301A BR0214301A BR 0214301 A BR0214301 A BR 0214301A BR 0214301 A BR0214301 A BR 0214301A BR 0214301 A BR0214301 A BR 0214301A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- gabaa receptor
- salt
- alter
- pharmaceutically acceptable
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 150000003839 salts Chemical class 0.000 title abstract 4
- 239000003795 chemical substances by application Substances 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 230000000694 effects Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 title abstract 2
- 230000019491 signal transduction Effects 0.000 title abstract 2
- 102000027484 GABAA receptors Human genes 0.000 title 2
- 108091008681 GABAA receptors Proteins 0.000 title 2
- 201000010099 disease Diseases 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 210000003169 central nervous system Anatomy 0.000 abstract 3
- 229960003692 gamma aminobutyric acid Drugs 0.000 abstract 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 abstract 2
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 abstract 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical class NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 abstract 1
- 229940049706 benzodiazepine Drugs 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 206010025482 malaise Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33302701P | 2001-11-19 | 2001-11-19 | |
| PCT/US2002/037157 WO2003044018A1 (en) | 2001-11-19 | 2002-11-19 | 1h-pyrrolo[3,2-b]pyridine-3-carboxylic acid amides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0214301A true BR0214301A (pt) | 2004-10-13 |
Family
ID=23300941
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0214301-1A BR0214301A (pt) | 2001-11-19 | 2002-11-19 | Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos para tratar doenças ou condições, para potencializar um efeito terapêutico de um agente do snc, para melhorar a memória recente de um paciente, para determinar a presença ou ausência de um receptor de gabaa em uma amostra, e para alterar a atividade de transdução de sinal de receptor de gabaa, preparação farmacêutica acondicionada, e, uso de um composto ou sal |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1453831A1 (enExample) |
| JP (1) | JP2005516901A (enExample) |
| AU (1) | AU2002366092A1 (enExample) |
| BR (1) | BR0214301A (enExample) |
| CA (1) | CA2467542A1 (enExample) |
| MX (1) | MXPA04004711A (enExample) |
| WO (1) | WO2003044018A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2865208B1 (fr) * | 2004-01-16 | 2009-01-16 | Sanofi Synthelabo | Derives de 1,4-diazabicyclo[3.2.1]octanecarboxmique, leur preparation et leur application en therapeutique |
| FR2890072A1 (fr) * | 2005-09-01 | 2007-03-02 | Fournier S A Sa Lab | Nouveaux composesde pyrrolopyridine |
| US20150374705A1 (en) | 2012-02-14 | 2015-12-31 | Shanghai Institues for Biological Sciences | Substances for treatment or relief of pain |
| WO2014196793A1 (en) | 2013-06-05 | 2014-12-11 | C&C Research Laboratories | Heterocyclic derivatives and use thereof |
| GB201317363D0 (en) | 2013-10-01 | 2013-11-13 | Eisai Ltd | Novel compounds |
| CN116102549B (zh) * | 2021-11-09 | 2025-02-11 | 暨南大学 | 5-醛基杂环酰胺类化合物及其应用 |
| WO2023082044A1 (zh) * | 2021-11-09 | 2023-05-19 | 暨南大学 | 5-醛基杂环酰胺类化合物及其应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5750702A (en) * | 1993-10-27 | 1998-05-12 | Neurogen Corporation | Certain pyrrolo pyridine-3-carboxamides; a new class of GABA brain receptor ligands |
-
2002
- 2002-11-19 JP JP2003545655A patent/JP2005516901A/ja active Pending
- 2002-11-19 CA CA002467542A patent/CA2467542A1/en not_active Abandoned
- 2002-11-19 AU AU2002366092A patent/AU2002366092A1/en not_active Abandoned
- 2002-11-19 MX MXPA04004711A patent/MXPA04004711A/es active IP Right Grant
- 2002-11-19 WO PCT/US2002/037157 patent/WO2003044018A1/en not_active Ceased
- 2002-11-19 EP EP02803679A patent/EP1453831A1/en not_active Withdrawn
- 2002-11-19 BR BR0214301-1A patent/BR0214301A/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1453831A1 (en) | 2004-09-08 |
| JP2005516901A (ja) | 2005-06-09 |
| WO2003044018A1 (en) | 2003-05-30 |
| MXPA04004711A (es) | 2005-08-16 |
| AU2002366092A1 (en) | 2003-06-10 |
| CA2467542A1 (en) | 2003-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0108977B8 (pt) | compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo | |
| EP1465666A4 (en) | MULTIPLE COMPONENT ARRANGEMENT WITH IMPROVED BINDING CHARACTERISTICS FOR DIAGNOSIS AND THERAPY | |
| DE60134453D1 (de) | Pharmazeutische Zusammensetzungen zur Behandlung von ZNS und anderen Krankheiten | |
| DE60126980D1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
| NZ504026A (en) | Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C | |
| PL320822A1 (en) | Sulphonamidic compounds as therapeutic agents for treatment of central nervous system, method of obtaining novel sulphonamidic compounds and drugs containing such compounds | |
| BR0205722A (pt) | Formulação de liberação prolongada e método para o tratamento de um paciente que sofre de dor | |
| EP1622663A4 (en) | DEVICE AND METHOD FOR DISTRIBUTING THERAPEUTIC AND / OR DIAGNOSTIC MEANS | |
| CA2379695A1 (en) | Compounds for modulating the rage receptor | |
| BR9802537A (pt) | Método para anestesiar um paciente humano antes de cirurgias de porte dose unitária e sistema farmacêutico para administração | |
| BR0313718A (pt) | Composto, processo para a preparação do mesmo, composição farmacêutica, métodos para tratar um indivìduo humano ou animal sofrendo de uma condição que é mediada por cox-2 e para tratar um indivìduo humano ou animal sofrendo de um distúrbio inflamatório, e, uso de um composto | |
| EP0779889A4 (en) | PYRAZOLO 3,4-g]QUINOXALINE COMPOUNDS WHICH INHIBIT PDGF RECEPTOR PROTEIN TYROSINE KINASE | |
| PT946162E (pt) | Utilizacao de derivados do p-aminofenol para a preparacao de composicoes farmaceuticas uteis no tratamento de doencas neurodegenerativas | |
| EE9900275A (et) | CD40L-vastaste ühendite terapeutilise manustamise meetodid | |
| BR0208241A (pt) | Composto, composições farmacêutica métodos para o tratamento de ansiedade, depressão, um distúrbio do sono, distúrbio de déficit de atenção, ou demência de alzheimer, para aumentar a potência de um efeito terapêutico de um agente do cns, para determinar a presença ou ausência de receptor de gabaa em uma amostra, e para alterar a atividade de transdução de sinal de receptor de gabaa, e, uso de um composto | |
| BR0212249A (pt) | Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto | |
| WO2004041809A3 (en) | Substituted imidazolylmethyl pyridine and pyrazine derivatives and their use as gabaa receptor ligands | |
| TW374085B (en) | Novel piperidine derivatives, their preparation, pharmaceutical formulation and medical use | |
| DE69514100D1 (de) | Substituierte kondensierte und verbrückte bicyclische verbindungen als therapeutische mittel | |
| IL153577A0 (en) | Pharmaceutical compositions and methods for use | |
| BR9814867A (pt) | Método para tratar discinesias relacionadas a doenças ou induzidas por drogas | |
| BRPI0412908A (pt) | composto ou um sal deste farmaceuticamente aceitável, composição farmacêutica, métodos para o tratamento de ansiedade, depressão, um distúrbio do sono, distúrbio de déficit de atenção ou demência de alzheimer, para potenciar um efeito terapêutico de um agente do cns, para melhorar a memória de curta duração em um paciente, para alterar a atividade de transdução de sinal de receptor gabaa, e para determinar a presença ou ausência de receptor gabaa em uma amostra, preparação farmacêutica acondicionada, e, uso de um composto ou sal | |
| WO2004031174A8 (en) | Imidazol-1-ylmethyl pyridazine derivatives | |
| WO2000076500A8 (en) | Compound for use as a medicament for treatment of disorders involving bronchocontraction | |
| AU2003276514A1 (en) | 4-imidazol-1-ylmethyl-pyrimidine derivatives_as ligands for gabaa receptors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07A | Technical examination (opinion): publication of technical examination (opinion) | ||
| B08F | Application fees: dismissal - article 86 of industrial property law |
Free format text: REFERENTE A 9A ANUIDADE. |
|
| B08K | Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87) |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2162 DE 12/06/2012. |